Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / FDA issues CRL for Sobi's NASP
Regulatory regulatory decision

FDA issues CRL for Sobi's NASP

Analysis based on 7 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026

Sentiment
-20
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is likely to react negatively to Swedish Orphan Biovitrum's stock due to the delay in National Association of Securities Professionals's approval, as this impacts future revenue potential. The pharmaceutical industry may see this as a reminder of the stringent regulatory hurdles for new drug approvals.

pharmaceuticals biotechnology
Event Summary

Swedish Orphan Biovitrum received a Complete Response Letter (CRL) from the United States — Food and Drug Administration for its Biologics License Application for National Association of Securities Professionals, a drug for uncontrolled gout. The CRL primarily requests additional data related to chemistry, manufacturing, and controls (CMC) and addresses deficiencies at contract manufacturing facilities. No concerns regarding clinical efficacy or safety were identified. Swedish Orphan Biovitrum plans to meet with the United States — Food and Drug Administration to discuss the feedback and determine the steps for resubmission, reaffirming its commitment to bringing National Association of Securities Professionals to patients.

Entities Involved
stock
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum received a Complete Response Letter from the FDA for its Biologics License Application for National Association of Securities Professionals, requiring additional data and addressing facility deficiencies. This delays the approval process for their drug.
Importance 100.0 Sentiment -30.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a Complete Response Letter to Swedish Orphan Biovitrum, requesting more data and facility improvements for National Association of Securities Professionals, thus impacting the drug's approval timeline.
Importance 90.0 Sentiment 0.0
oth
National Association of Securities Professionals
National Association of Securities Professionals, an investigational medicine for uncontrolled gout, faces a delay in its approval process due to the United States — Food and Drug Administration's request for additional manufacturing data and facility improvements.
Importance 80.0 Sentiment -20.0
per
Lydia Abad-Franch
Lydia Abad-Franch, Chief Medical Officer at Swedish Orphan Biovitrum, expressed continued belief in National Association of Securities Professionals's potential despite the regulatory setback.
Importance 30.0 Sentiment 0.0
cnt
United States
The United States is the market where the drug National Association of Securities Professionals is seeking approval from the United States — Food and Drug Administration, affecting patients with gout in this country.
Importance 20.0 Sentiment 0.0
exch
Nasdaq Stockholm
Nasdaq Stockholm is where Swedish Orphan Biovitrum's shares are listed, and the news of the FDA's CRL could potentially affect its stock performance.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.